Report DMCA A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin recepto
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.